Friday, 28 August 2015

Government launches telemedicine initiative 'Sehat'


Today’s economic times reports the launch of the service named ‘Sehat’. This service is aimed to provide healthcare facilities in rural areas. The government of India launched this telemedicine initiative in collaboration with Apollo Hospitals under which people can consult doctors through video link.

As part of the service named 'Sehat', people in rural areas can consult doctors online and also order generic drugs.

The Common Service Centres (CSCs) have been delivering tele-consultation services with support from Apollo and Medanta in some areas and now with this initiative the tele- consultation services are being extended to 60,000 CSCs across the country.

"Quality and affordable healthcare is one of the emerging need for citizens in rural areas. I am happy that CSC SPV and Apollo have come together to address this issue and design a workable solution," Communications and IT Minister Ravi Shankar Prasad said while launching the service.

The CSCs will also provide diagnostic services and promote sale of generic drugs through collaboration with Ministry of Health, by setting up Jan Aasudhi Stores.

"With the availability of tele-consultation, diagnostic facilities and generic drugs stores, we can redefine the extension of affordable and quality healthcare to the citizen especially in rural India," Prasad said.

Under the service, people can visit CSCs and fix an appointment for seeking expert consultancy with a doctor.

The doctors at Apollo Hospitals will be able to provide consultancy to the patients using the video link facilities.

http://economictimes.indiatimes.com/industry/healthcare/biotech/healthcare/government-launches-telemedicine-initiative-sehat/articleshow/48670278.cms



September 2015 Issue of Pharma Literati Magazine

The September, 2015 issue of Pharma Literati Magazine is available now. Please visit the same at: http://www.issuu.com/pharmaliterati/docs/september_2015_magazine

The collaborators and the subscribers who have requested e-copy would get the PDF version of the same via email over next two days. The faculties/ researchers/ students are requested to share it via e-platforms and/or notice board. 

Happy reading. 


Thursday, 27 August 2015

Amazing story about rare genetic disorder and its cure

Times of India reports an amazing story about Cystinosis and the treatment available for the same. 


Only 11 Of 19 Children In India Diagnosed With Cystinosis Are Alive Researchers in IIT Madras have developed a life-saving drug that can keep children suffering from a rare genetic disorder alive. There are only 11 children in the country who suffer from the condition called cystinosis. The drug, if made and marketed in the country, will bring relief to the parents of these children who at present import them from Europe at a huge price as it is not approved in India.

Children with cystinosis suffer from growth retardation, kidney failure, bone deformities like rickets and blindness. In India, only 19 children have so far been diagnosed with the disorder, and nine of them are no more.

Cystinosis Foundation, India has collaborated with IIT-M to make the drug Cysteamine Bitartrate to treat the disorder, which is now in the final stages of development. Professor in the Chemistry department S Sankaraman said they are now in the process of purifying the compound. "We began developing the drug a year back. It will be ready in another one or two months' time," he said. The drug is now being manufactured by Orphan Europe, a firm headquartered in Paris. Parents in India import the drug once in every three months from there.

Nephrologist Dr Rajan Ravichandran said the drug removes the amino acid cysteine that accumulates in cells. The patients have to be given the drug once every six hours. Though it is not a cure, it can contain the disorder. However, the drug is very expensive. "For a three-month course, it costs about `2 lakh. There is also the customs duty, which is 10% to 15%," he said.

According to the Drugs and Cosmetics Rules, 1945, an individual can import lifesaving drugs in small quantities upon obtaining a permit from the Drugs Controller General. "Every time we have to obtain permission. It is a very tedious procedure to import these drugs," said Sujatha Sivarasu, mother of two boys who were diagnosed with the disorder.

Dr. Ravichandran said pharmaceutical companies do not manufacture or market the drug in India as it has no commercial value since there are only 11 known consumers. Further, to get the controller's approval to commercialise the drug in India, extensive clinical trials are needed . "But we cannot have a trial as we need large sample size," the Dr. Ravichandran said."Fortunately, the Madras high court has given a direction asking the controller to approve the drug without clinical trials as it is a life-saving drug. Also, the patent for the drug made in Europe has expired as it is more than 25 years old," he said.

A pharmaceutical company has volunteered to make and market the drug. "We have to scale it up and formulate it into a capsule or tablet. It would be made available at a nominal price," Dr. Ravichandran said. Only 11 Of 19 Children In India Diagnosed With Cystinosis Are Alive Researchers in IIT Madras have developed a life-saving drug that can keep children suffering from a rare genetic disorder alive. There are only 11 children in the country who suffer from the condition called cystinosis. The drug, if made and marketed in the country , will bring relief to the parents of these children who at present import them from Europe at a huge price as it is not approved in India.

Children with cystinosis suffer from growth retardation, kidney failure, bone deformities like rickets and blindness. In India, only 19 children have so far been diagnosed with the disorder, and nine of them are no more.

Cystinosis Foundation, India has collaborated with IIT-M to make the drug Cysteamine Bitartrate to treat the disorder, which is now in the final stages of development. Professor in the Chemistry department S Sankaraman said they are now in the process of purifying the compound. "We began developing the drug a year back.It will be ready in another one or two months' time," he said. The drug is now being manufactured by Orphan Europe, a firm headquartered in Paris. Parents in India import the drug once in every three months from there.

Nephrologist Dr Rajan Ravichandran said the drug removes the amino acid cysteine that accumulates in cells. The patients have to be given the drug once every six hours. Though it is not a cure, it can contain the disorder. However, the drug is very expensive. "For a three-month course, it costs about `2 lakh. There is also the customs duty , which is 10% to 15%," he said.

According to the Drugs and Cosmetics Rules, 1945, an individual can import lifesaving drugs in small quantities upon obtaining a permit from the Drugs Controller General. "Every time we have to obtain permission. It is a very tedious procedure to import these drugs," said Sujatha Sivarasu, mother of two boys who were diagnosed with the disorder.

Dr Ravichandran said pharmaceutical companies do not manufacture or market the drug in India as it has no commercial value since there are only 11 known consumers. Further, to get the controller's approval to commercialise the drug in India, extensive clinical trials are needed . "But we cannot have a trial as we need large sample size," the Dr Ravichandran said."Fortunately , the Madras high court has given a direction asking the controller to approve the drug without clinical trials as it is a life-saving drug. Also, the patent for the drug made in Europe has expired as it is more than 25 years old," he said.

A pharmaceutical company has volunteered to make and market the drug. "We have to scale it up and formulate it into a capsule or tablet. It would be made available at a nominal price," Dr Ravichandran said. Only 11 Of 19 Children In India Diagnosed With Cystinosis Are Alive Researchers in IIT Madras have developed a life-saving drug that can keep children suffering from a rare genetic disorder alive. There are only 11 children in the country who suffer from the condition called cystinosis. The drug, if made and marketed in the country , will bring relief to the parents of these children who at present import them from Europe at a huge price as it is not approved in India.

Children with cystinosis suffer from growth retardation, kidney failure, bone deformities like rickets and blindness. In India, only 19 children have so far been diagnosed with the disorder, and nine of them are no more.

Cystinosis Foundation, India has collaborated with IIT-M to make the drug Cysteamine Bitartrate to treat the disorder, which is now in the final stages of development. Professor in the Chemistry department S Sankaraman said they are now in the process of purifying the compound. "We began developing the drug a year back.It will be ready in another one or two months' time," he said. The drug is now being manufactured by Orphan Europe, a firm headquartered in Paris. Parents in India import the drug once in every three months from there.

Nephrologist Dr Rajan Ravichandran said the drug removes the amino acid cysteine that accumulates in cells. The patients have to be given the drug once every six hours. Though it is not a cure, it can contain the disorder. However, the drug is very expensive. "For a three-month course, it costs about `2 lakh. There is also the customs duty , which is 10% to 15%," he said.

According to the Drugs and Cosmetics Rules, 1945, an individual can import lifesaving drugs in small quantities upon obtaining a permit from the Drugs Controller General. "Every time we have to obtain permission. It is a very tedious procedure to import these drugs," said Sujatha Sivarasu, mother of two boys who were diagnosed with the disorder.

Dr Ravichandran said pharmaceutical companies do not manufacture or market the drug in India as it has no commercial value since there are only 11 known consumers. Further, to get the controller's approval to commercialise the drug in India, extensive clinical trials are needed . "But we cannot have a trial as we need large sample size," the Dr Ravichandran said."Fortunately , the Madras high court has given a direction asking the controller to approve the drug without clinical trials as it is a life-saving drug. Also, the patent for the drug made in Europe has expired as it is more than 25 years old," he said.

A pharmaceutical company has volunteered to make and market the drug. "We have to scale it up and formulate it into a capsule or tablet. It would be made available at a nominal price," Dr Ravichandran said. Only 11 Of 19 Children In India Diagnosed With Cystinosis Are Alive Researchers in IIT Madras have developed a life-saving drug that can keep children suffering from a rare genetic disorder alive. There are only 11 children in the country who suffer from the condition called cystinosis. The drug, if made and marketed in the country , will bring relief to the parents of these children who at present import them from Europe at a huge price as it is not approved in India.

Children with cystinosis suffer from growth retardation, kidney failure, bone deformities like rickets and blindness. In India, only 19 children have so far been diagnosed with the disorder, and nine of them are no more.

Cystinosis Foundation, India has collaborated with IIT-M to make the drug Cysteamine Bitartrate to treat the disorder, which is now in the final stages of development. Professor in the Chemistry department S Sankaraman said they are now in the process of purifying the compound. "We began developing the drug a year back.It will be ready in another one or two months' time," he said. The drug is now being manufactured by Orphan Europe, a firm headquartered in Paris. Parents in India import the drug once in every three months from there.

Nephrologist Dr Rajan Ravichandran said the drug removes the amino acid cysteine that accumulates in cells. The patients have to be given the drug once every six hours. Though it is not a cure, it can contain the disorder. However, the drug is very expensive. "For a three-month course, it costs about `2 lakh. There is also the customs duty , which is 10% to 15%," he said.

According to the Drugs and Cosmetics Rules, 1945, an individual can import lifesaving drugs in small quantities upon obtaining a permit from the Drugs Controller General. "Every time we have to obtain permission. It is a very tedious procedure to import these drugs," said Sujatha Sivarasu, mother of two boys who were diagnosed with the disorder.

Dr Ravichandran said pharmaceutical companies do not manufacture or market the drug in India as it has no commercial value since there are only 11 known consumers. Further, to get the controller's approval to commercialise the drug in India, extensive clinical trials are needed . "But we cannot have a trial as we need large sample size," the Dr Ravichandran said."Fortunately , the Madras high court has given a direction asking the controller to approve the drug without clinical trials as it is a life-saving drug. Also, the patent for the drug made in Europe has expired as it is more than 25 years old," he said.

A pharmaceutical company has volunteered to make and market the drug. "We have to scale it up and formulate it into a capsule or tablet. It would be made available at a nominal price," Dr Ravichandran said. Only 11 Of 19 Children In India Diagnosed With Cystinosis Are Alive Researchers in IIT Madras have developed a life-saving drug that can keep children suffering from a rare genetic disorder alive. There are only 11 children in the country who suffer from the condition called cystinosis. The drug, if made and marketed in the country , will bring relief to the parents of these children who at present import them from Europe at a huge price as it is not approved in India.

Children with cystinosis suffer from growth retardation, kidney failure, bone deformities like rickets and blindness. In India, only 19 children have so far been diagnosed with the disorder, and nine of them are no more.

Cystinosis Foundation, India has collaborated with IIT-M to make the drug Cysteamine Bitartrate to treat the disorder, which is now in the final stages of development. Professor in the Chemistry department S Sankaraman said they are now in the process of purifying the compound. "We began developing the drug a year back.It will be ready in another one or two months' time," he said. The drug is now being manufactured by Orphan Europe, a firm headquartered in Paris. Parents in India import the drug once in every three months from there.

Nephrologist Dr Rajan Ravichandran said the drug removes the amino acid cysteine that accumulates in cells. The patients have to be given the drug once every six hours. Though it is not a cure, it can contain the disorder. However, the drug is very expensive. "For a three-month course, it costs about `2 lakh. There is also the customs duty , which is 10% to 15%," he said.

According to the Drugs and Cosmetics Rules, 1945, an individual can import lifesaving drugs in small quantities upon obtaining a permit from the Drugs Controller General. "Every time we have to obtain permission. It is a very tedious procedure to import these drugs," said Sujatha Sivarasu, mother of two boys who were diagnosed with the disorder.

Dr Ravichandran said pharmaceutical companies do not manufacture or market the drug in India as it has no commercial value since there are only 11 known consumers. Further, to get the controller's approval to commercialise the drug in India, extensive clinical trials are needed . "But we cannot have a trial as we need large sample size," the Dr Ravichandran said."Fortunately , the Madras high court has given a direction asking the controller to approve the drug without clinical trials as it is a life-saving drug. Also, the patent for the drug made in Europe has expired as it is more than 25 years old," he said.

A pharmaceutical company has volunteered to make and market the drug. "We have to scale it up and formulate it into a capsule or tablet. It would be made available at a nominal price," Dr Ravichandran said.

Source: http://timesofindia.indiatimes.com/city/chennai/ALMOST-THERE-IIT-M-develops-drug-for-rare-genetic-disorder/articleshow/48690806.cms

Dr. Girish Sahni assumed charge as next Director General of Council of Scientific & Industrial Research


Dr. Girish Sahni on August 24, 2015 assumed the charge as next Director General of Council of Scientific & Industrial Research (CSIR).  Earlier, he was the director of CSIR-Institute of Microbial Technology (CSIR-IMTECH), Chandigarh. He has contributed significantly in the area of protein cardiovascular drugs especially clot busters and their mode of action in the human body.

About Dr. Girish sahni
Dr Sahni is a PhD from Indian institute of Science (IISc), Bangaluru. His post PhD career included a stint each in University of California, Santa Barbara, CA, USA: Postdoc Trainee 1984-86; Rockefeller University New York, USA: Sr. Research Associate and Adjunct Faculty 1986-88; and Albert Einstein College of Medicine, New York: Sr. Research Associate 1987-91, before he joined CSIR-IMTECH in 1991 and became its Director in 2005.

His achievements
The team led by him is responsible for producing technology for India’s first indigenous clot bluster drug, natural streptokinase (under brand name ‘STPase’ marketed by Cadila Pharmaceuticals Ltd., Ahmedabad), and recombinant streptokinase (produced by Shasun Drugs, Chennai) marketed as several brand names eg. ‘Klotbuster’ (Alembic) and ‘LupiFlo’ (Lupin). His team has also developed a novel life-saver thrombolytic drug (Clot-specific streptokinase), India’s first bio-therapeutic molecule which is not a Biosimilar. This life-saver drug has been patented world wide and licensed to a US Pharma company for which the commercial launch is expected in 2016. Recently, the team led by him developed fourth-generation ‘Anti-thrombotic’ clot busters – the first of its kind in the world.

Dr. Sahni is internationally recognized for his research contributions. He has been the author of several papers published in high impact refereed scientific journals and has a number of national and international patents to his credit.

His awards
Amongst the many awards he has received for his contributions, the most important ones are: National Biotechnology Product Development Award 2002, CSIR Technology Shield 2001-2002, The Vasvik Industrial Award 2000, Ranbaxy Award in Pharmaceutical Sciences 2003, Vigyan Rattan Award 2014, Shri Om Prakash Bhasin Award 2013, and CSIR Technology Award for Business Development and Technology Marketing 2014.

Source: http://www.prepsure.com/news/dr-girish-sahni-assumed-charge-as-next-director-general-of-council-of-scientific-industrial-research/

One thousand crore fund for Pharma Start-ups likely


Indian Express reports that the Union government is planning to come out with a Rs 1,000 crore venture capital fund to promote start-ups on drug discovery.

Addressing the inaugural round-table session on ‘Bio and Pharma 2015’, organised by the Confederation of Indian Industry in Chennai,  Union joint secretary of Department of Pharmaceuticals M Ariz Ahammed said that the idea was in the nascent stage and refused to divulge further details.

“The disease burden in India is shifting from communicable to non-communicable and the drugs available are already patented. Post-WTO, there is an urgent need to discover new drugs or else affordability would be a big issue,” he said.  

Source: http://www.newindianexpress.com/business/news/Rs-1K-cr-VC-Fund-for-Pharma-Start-ups-likely/2015/08/27/article2995210.ece



Tuesday, 25 August 2015

Meet our bloggers_Ajinkya Supekar


Dear All,
We had posted about bloggers joining our team.
See http://pharmaliterati.blogspot.in/2015/05/bloggers-required.html

We are pleased to welcome our sixth blogger in the series, Ajinkya Supekar. He has done his M. Pharmacy from BITS, Pilani and his graduation from M. V. P. College of Pharmacy, Pune University.

We welcome Ajinkya to our team and wish a luck in the endeavor. 

To join as a blogger with Pharma Literati team, send your CV to pharmaliterati@gmail.com

Team Pharma Literati. 

Pharma academic research - Indian patent applications published on 21st August 2015


Every week of thousands of patent applications are published in India. The patent applications filed by the pharma academic research institutes in India go un-noticed.

We publish a list of Indian applications published related to pharma academics. This would provide us an idea about the kind of academic research being carried out in these institutes. For details of these patents, please write back to us at pharmaliterati@gmail.com

Invention
Application No
Inventors
Institute
Curcumin coated superparamagnetic iron oxide nanoparticles for biomedical applications
138/DEL/2012 A
1) Pattayil Alias Joy
2) Jayaprabha Kunnoth Naduvilidam
CSIR
Novel prebiotic product for treating hemorrhoid
171/DEL/2012 A
1) Harsha Kharkwal
2) Devi Datt Joshi
3) Deepshikha Pande Katare
4) Kumud Bala
Amity University
Novel functional food supplement for use as adjuvant therapy in the prevention of oxidative stress and associated disorders
170/DEL/2012 A
1) Dhan Prakash
2) Charu Gupta
Amity University
Novel one step process for preparation of compositions comprising nanocrystalline solid dispersions
674/DEL/2012 A
1) Arvind Kumar Bansal
2) Ajay Kumar Raju Dantuluri
NIPER, Mohali
Novel curcumin-drug conjugates
731/DEL/2012 A
1) Sandeep Kumar Jain
2) Sarasija Suresh
3) Manjinder Singh Gill
NIPER, Mohali
Multi-component crystalline form of oxcarbazepine
833/DEL/2012 A
1) Renu Chadha
Punjab University
Thermogelling composition and method of preparation of the same
29/MUM/2014 A
1) Patel Gayatri Chhaganbhai
2) Dalwadi Chintan Arvindbhai
3) Parikh Rajesh Harshadray
Charotar University of Science & Technology
4-(1,3-dioxoisoindolin-2-yl)-benzenesulfonamide derivatives, their synthesis, antiviral activity and methods thereof
191/KOL/2014 A
1) Barij Nayan Sinha
2) Ajay Kumar Timiri
3) Venkatesan Jayaprakash
Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi-835215 Jharkhand.
Controlled release mucoadhesive microcapsules of venlafaxine
190/KOL/2014 A
1) Dr. Suryakanta Swain
2) Dr. Chinam Niranjan Patra
3) Dr. Muddana Eswara Bhanoji Rao
4) Srikanta Patra
Dept. of Pharmaceutics, Roland Institute of Pharmaceutical Sciences, Khodasingi, Berhampur, Odisha

Friday, 21 August 2015

Unique Mobile Application on HIV/AIDS launched by Union Health Ministry


The Ministry of Health and Family Welfare in collaboration with AIDS Healthcare Foundation, Department of Telecommunications and National AIDS Control Organization announced the launch of a new mobile application on HIV/AIDS today. This mobile application will provide complete information on HIV, increase awareness and risk perception as well as prompt users to access HIV testing from the nearest centre free of cost. Ensuring confidentiality, with bi-lingual facility and easy compatibility, it is expected to reach more than 11 crore people across urban & rural settings.

Speaking at the occasion, J.P. Nadda, Union Minister of Health and Family Welfare said that, "Technology and youth are inseparable; however, inadequate access to information and complex messages from various sources can confuse the youth. If we can use technology to guide and educate youth, it can open up endless opportunities to reach the young with authentic information on the services on HIV and AIDS. There is a dire need to motivate, inform and guide them. This mobile application, aptly titled, HIV education and linkage to prevention (HELP), will bridge the gap helping the youth to know their HIV status. It will transmit information personally to each of them which is a step ahead of door to door health services."

Navneet S Kang, Additional Secretary and DG, NACO stated that "HIV affects the people most at the productive or young ages. There is a gap between the estimated number of people living with HIV and those who have tested and know their status. It is critical that people know their HIV status early so that a healthy and quality life can be led with the help of treatment. This application will enable the young to assess their risk to HIV and then, take a step forward and get themselves tested. NACO acknowledges the support of AIDS Healthcare Foundation for developing this mobile App for HIV." This new mobile App on HIV will be taken further to the block level by DoT with the help of BSNL & MTNL to cover rural youth across the country. 


See more at: http://www.biospectrumindia.com/biospecindia/news/222193/unique-mobile-application-hiv-aids-launched-union-health-ministry#sthash.ND2MH428.dpuf

Thursday, 20 August 2015

Blog updates


The days, weeks and months are passing rapidly. There are lots of activities happening with reference to our beloved blog. With limited time and resources, we are trying to get the best of the resources and news and information for the pharma community. Here is a quick recap of the activities for those who have joined us recently:

Collaborations:
FICCI – CCIPR
http://pharmaliterati.blogspot.in/2015/06/pharma-literati-collaborates-with-ficci.html
Pharma career
http://pharmaliterati.blogspot.in/2015/06/collaboration-with-pharmacareer.html

Social Media presence:
Linkedin
http://pharmaliterati.blogspot.in/2015/06/pharma-literati-on-linkedin.html
Mobile app
http://pharmaliterati.blogspot.in/2015/06/pharma-literati-available-on-mobile-app.html
Facebook
http://pharmaliterati.blogspot.in/2015/07/pharma-literatinow-has-facebook-page.html
WhatsAPP
09769059971
Issuu
http://www.issuu.com/pharmaliterati/

Subscription information:
Subscriptions
210+ subscriptions as on 20th August 2015
Page views
6000+ Page views on the blog.

Our bloggers recently joined:
Kabin Maleku
http://pharmaliterati.blogspot.in/2015/06/meet-our-bloggerskabin-maleku.html
Pari Bhatt
http://pharmaliterati.blogspot.in/2015/06/meet-our-bloggerspari-bhatt.html
Mohi Durakshan
http://pharmaliterati.blogspot.in/2015/05/meet-our-bloggersmohi-durakshan.html
Jutika Pal
http://pharmaliterati.blogspot.in/2015/08/meet-our-bloggersjutika-pal.html
Powlami Ghosh
http://pharmaliterati.blogspot.in/2015/08/meet-our-bloggerspowlami-ghosh.html

Weekly/Monthly Activities:
Upcoming events
See the last update as on 8th July 2015
http://pharmaliterati.blogspot.in/2015/07/upcoming-events.html
Monthly magazine
See the e-copy 
http://issuu.com/pharmaliterati/docs/august_2015_magazine
Patent applications published by pharmacy institutes
See the last update as on 14th August 2015
http://pharmaliterati.blogspot.in/2015/08/pharma-academic-research-indian-patent_18.html
Students career guidance centre
Send a query to 09769059971

Please send us your feedback, updates, events, criticisms or anything worth sharing to our email ID: pharmaliterati@gmail.com